LLY logo Eli Lilly and Company +
Eli Lilly and Company
+

Eli Lilly and Company (LLY) Business News

Track Eli Lilly and Company in real time with a live news feed covering Eli Lilly and Company stock news, official press releases, company announcements, and an archive of historical Eli Lilly and Company news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
12:00 AM | Tuesday | Jun 30, 2026 PRNewsWire

Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China

News Thumbnail
7:16 AM | Friday | Jun 26, 2026 PRNewsWire

Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy

News Thumbnail
6:45 AM | Thursday | Jun 25, 2026 PRNewsWire

What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management

News Thumbnail
8:45 AM | Wednesday | Jun 24, 2026 PRNewsWire

Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders

News Thumbnail
11:00 AM | Monday | Jun 22, 2026 PRNewsWire

Lilly declares third-quarter 2026 dividend

News Thumbnail
11:15 AM | Saturday | Jun 13, 2026 PRNewsWire

Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting

News Thumbnail
4:00 AM | Tuesday | Jun 9, 2026 Business Wire

Convatec and Lilly Foundation Commit $5m to Partners In Health to Improve Care for Non‑communicable Disease and Chronic Conditions

News Thumbnail
11:00 AM | Sunday | Jun 7, 2026 PRNewsWire

Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause

News Thumbnail
9:30 AM | Tuesday | Jun 2, 2026 PRNewsWire

Lilly to spotlight growing hematology portfolio at 2026 European Hematology Association (EHA) Annual Meeting

News Thumbnail
8:01 AM | Sunday | May 31, 2026 PRNewsWire

Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer

News Thumbnail

Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China

PRNewsWire

12:00 AM | Tuesday | Jun 30, 2026

news photo
Loading...

SAN FRANCISCO and SUZHOU, China, June 30, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, and Eli Lilly and Company (NYSE: LLY) today jointly announced that they have entered into a distribution and promotion agreement regarding Lilly's CDK4 & 6 inhibitor Verzenios® (abemaciclib) in mainland China: Innovent will be responsible for the importation, marketing, distribution and promotion of Verzenios® (abemaciclib) in mainland China; Lilly will continue to be responsible for manufacturing, supply, and development for the product. Verzenios® (abemaciclib), developed by Lilly, is a CDK4 & 6 inhibitor that has been approved in China for multiple indications, including: (1) Early Breast Cancer: in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence.

Read full article redirect
12:00 AM | Tuesday | Jun 30, 2026

Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China

PRNewsWire

SAN FRANCISCO and SUZHOU, China, June 30, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, and Eli Lilly and Company (NYSE: LLY) today jointly announced that they have entered into a distribution and promotion agreement regarding Lilly's CDK4 & 6 inhibitor Verzenios® (abemaciclib) in mainland China: Innovent will be responsible for the importation, marketing, distribution and promotion of Verzenios® (abemaciclib) in mainland China; Lilly will continue to be responsible for manufacturing, supply, and development for the product. Verzenios® (abemaciclib), developed by Lilly, is a CDK4 & 6 inhibitor that has been approved in China for multiple indications, including: (1) Early Breast Cancer: in... Read more

Read full article arrow
News Thumbnail
7:16 AM | Friday | Jun 26, 2026

Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy

PRNewsWire

The positive opinion is based on results from the Phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials, previously presented at the 2025 American Society of Hematology Annual Meeting and published in The Journal of Clinical Oncology BRUIN CLL-313 is the first Phase 3 study to evaluate a non-covalent BTK inhibitor exclusively in patients with treatment-naïve CLL and BRUIN CLL-314 is the first Phase 3 CLL trial to compare non-covalent and covalent BTK inhibitors, as well as the first to compare any BTK inhibitors in the treatment-naïve setting If granted marketing authorization, this would expand pirtobrutinib's indication as a treatment option for patients with CLL in the European Union across all lines of therapy INDIANAPOLIS, June 26, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the European Medicines Agency's (EMA) Committee for... Read more

Read full article arrow
News Thumbnail
6:45 AM | Thursday | Jun 25, 2026

What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management

PRNewsWire

A new Medicare pathway, the Medicare GLP-1 Bridge program, makes Lilly's obesity medicines – a daily pill or the number 1 most prescribed injectable – accessible to eligible Medicare Part D patients beginning July 1 INDIANAPOLIS, June 25, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced additional details regarding the Medicare GLP-1 Bridge* program taking effect July 1, 2026. Under the program, Medicare Part D patients may be able to access Foundayo (orforglipron) or Zepbound (tirzepatide) KwikPen for single-patient-use for weight management.

Read full article arrow
News Thumbnail
8:45 AM | Wednesday | Jun 24, 2026

Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders

PRNewsWire

INDIANAPOLIS, June 24, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Centessa Pharmaceuticals plc. Centessa is a clinical-stage company developing orexin receptor 2 agonists as a new class of medicines for the treatment of narcolepsy and potentially other sleep-wake disorders.

Read full article arrow
News Thumbnail
11:00 AM | Monday | Jun 22, 2026

Lilly declares third-quarter 2026 dividend

PRNewsWire

INDIANAPOLIS, June 22, 2026 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2026 of $1.73 per share on outstanding common stock. The dividend is payable on September 10, 2026, to shareholders of record at the close of business on August 14, 2026.

Read full article arrow
News Thumbnail
11:15 AM | Saturday | Jun 13, 2026

Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting

PRNewsWire

INDIANAPOLIS, June 13, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data from the Phase 1 AJX-101 study showing that its investigational type II JAK2 inhibitor (AJ1-11095) demonstrated an encouraging safety profile and promising clinical activity in patients with myelofibrosis who have been failed by a type I JAK2 inhibitor. This first-in-class type II JAK2 inhibitor was designed to selectively bind the type II conformation of the JAK2 kinase in order to potentially provide greater efficacy than existing therapies and a novel treatment option for patients who become resistant to type I JAK2 inhibitors.

Read full article arrow
News Thumbnail
4:00 AM | Tuesday | Jun 9, 2026

Convatec and Lilly Foundation Commit $5m to Partners In Health to Improve Care for Non‑communicable Disease and Chronic Conditions

Business Wire

LONDON & BOSTON--(BUSINESS WIRE)--Convatec (LSE:CTEC), a leading medical products and technologies company focused on solutions for the management of chronic conditions; The Eli Lilly and Company Foundation (Lilly Foundation), a tax-exempt private foundation supported by donations from Eli Lilly and Company (NYSE:LLY) have committed c.$5 million to Partners In Health (PIH), an international nonprofit global health organization to help accelerate the integration of non‑communicable disease (NCD).

Read full article arrow
News Thumbnail
11:00 AM | Sunday | Jun 7, 2026

Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause

PRNewsWire

In ATTAIN-1, women in perimenopause taking Foundayo lost up to 30.4 lbs (14.4%) and those in post-menopause lost up to 28.2 lbs (14.1%) In ATTAIN-2, women taking Foundayo lost significant weight across all stages of menopause, despite the additional challenge of living with type 2 diabetes Across studies, women taking Foundayo saw meaningful reductions in their waist circumference, a measure associated with reduced abdominal fat and cardiometabolic risk INDIANAPOLIS, June 7, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide), today announced results demonstrating that women with obesity or overweight who took the highest dose of Foundayo experienced significant weight loss at every stage of menopause.
These findings, based on post-hoc analyses of more than 1,500 female participants in the ATTAIN-1 and ATTAIN-2 clinical trials, were presented at the American Diabetes Association (ADA) 86th Scientific... Read more

Read full article arrow
News Thumbnail
9:30 AM | Tuesday | Jun 2, 2026

Lilly to spotlight growing hematology portfolio at 2026 European Hematology Association (EHA) Annual Meeting

PRNewsWire

Positive results from the Phase 3 BRUIN CLL-322 study comparing time-limited pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in patients with relapsed or refractory CLL/SLL will be highlighted in a late-breaking oral presentation Ajax Therapeutics, which Lilly has agreed to acquire, will present the first clinical data for its first-in-class type II JAK2 inhibitor for patients with myelofibrosis who have been failed by a type I JAK2 inhibitor Kelonia Therapeutics, which Lilly has agreed to acquire, will present additional correlative clinical data for its in vivo CAR-T program in patients with multiple myeloma  INDIANAPOLIS, June 2, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the details of presentations at the European Hematology Association (EHA) Annual Meeting, taking place June 11-14 in Stockholm, Sweden. Data to be... Read more

Read full article arrow
News Thumbnail
8:01 AM | Sunday | May 31, 2026

Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer

PRNewsWire

Phase 3 LIBRETTO-432 results establish RET fusions alongside EGFR mutations and ALK fusions as biomarkers in early-stage lung cancer that are associated with dramatic treatment outcomes, underscoring the importance of comprehensive biomarker testing across all stages of disease These data will be published in the New England Journal of Medicine and simultaneously presented during the Plenary Session at the 2026 ASCO Annual Meeting INDIANAPOLIS, May 31, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 LIBRETTO-432 clinical trial of Retevmo (selpercatinib) as adjuvant therapy versus placebo in patients with early-stage (IB-IIIA) rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC). The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in investigator-assessed event-free survival (EFS) with selpercatinib... Read more

Read full article arrow
News Thumbnail